Selecta Biosciences (SELB) Given Buy Rating at Canaccord Genuity
Selecta Biosciences (NASDAQ:SELB)‘s stock had its “buy” rating restated by equities research analysts at Canaccord Genuity in a research report issued to clients and investors on Wednesday. They presently have a $40.00 target price on the stock. Canaccord Genuity’s price objective would indicate a potential upside of 196.30% from the stock’s previous close.
The analysts wrote, “We expect Selecta to present positive 5-dose Phase 2 combination data for SEL-212 in severe gout during 3Q18, and see significant upside for the stock. Selecta is likely to present data from multiple dosing cohorts, with up to n=20 patients from each cohort. We suspect focus will be on the 0.15 mg/kg SVP-rapamycin + 0.20 pegsiticase dose, but await upcoming data. We see little reason that SEL-212 will not reproduce data at 5 months similar to that seen at 3 months, where ~80% Serum Uric Acid control was shown.””
SELB has been the subject of a number of other research reports. BidaskClub upgraded shares of Selecta Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 15th. Janney Montgomery Scott assumed coverage on shares of Selecta Biosciences in a report on Wednesday, June 27th. They set a “buy” rating and a $33.00 price objective for the company. ValuEngine upgraded shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Zacks Investment Research cut shares of Selecta Biosciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, March 21st. Finally, Mizuho restated a “buy” rating and set a $30.00 price objective on shares of Selecta Biosciences in a report on Wednesday, April 11th. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Selecta Biosciences has an average rating of “Buy” and an average price target of $28.25.
Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings data on Wednesday, May 9th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.11). Selecta Biosciences had a negative net margin of 31,556.04% and a negative return on equity of 111.69%. analysts expect that Selecta Biosciences will post -2.88 EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in the company. Alps Advisors Inc. boosted its holdings in shares of Selecta Biosciences by 21.0% in the first quarter. Alps Advisors Inc. now owns 29,958 shares of the company’s stock valued at $305,000 after buying an additional 5,207 shares during the period. Two Sigma Investments LP boosted its holdings in shares of Selecta Biosciences by 14.9% in the fourth quarter. Two Sigma Investments LP now owns 59,869 shares of the company’s stock valued at $587,000 after buying an additional 7,773 shares during the period. BlackRock Inc. boosted its holdings in shares of Selecta Biosciences by 1.6% in the first quarter. BlackRock Inc. now owns 629,978 shares of the company’s stock valued at $6,420,000 after buying an additional 9,749 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Selecta Biosciences by 12.1% in the fourth quarter. Geode Capital Management LLC now owns 92,803 shares of the company’s stock valued at $910,000 after buying an additional 9,988 shares during the period. Finally, DRW Securities LLC acquired a new position in shares of Selecta Biosciences in the first quarter valued at approximately $122,000. Institutional investors own 46.03% of the company’s stock.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.